A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Both insufficiency and deficiency of serum vitamin D correlated with an increased risk of unfavorable pathology in men undergoing radical prostatectomy for prostate cancer.
Older black men with localized prostate cancer were more likely to have poorer quality care, incur higher costs, and have worse postoperative outcomes than white men. However, that did not translate to worse overall or cancer-specific survival.
A recent study indicates a high rate of clinical upgrading at prostatectomy, based on over ten thousand patients reviewed.
Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.
Variation was observed at a high-volume center when surgeons selected patients with low-risk prostate cancer to undergo radical prostatectomy, according to a study.
Phosphodiesterase type 5 inhibitors up the risk of biochemical recurrence after radical prostatectomy, according to a recent study.
The endorsed guideline outlines use of adjuvant and salvage radiotherapy after surgery for prostate cancer.
For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.
Claims of not receiving proper informed consent and clinical performance are the main issues that arise in radical prostatectomy malpractice lawsuits.
Risk of long-term mortality for those that undergo surgical treatment is lower, compared with men who choose watchful waiting.
Robot-assisted radical prostatectomy (RARP) is associated with improved surgical margin status compared with open radical prostatectomy (ORP) for intermediate- and high-risk disease.
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have set forth several recommendations on radiation therapy after prostatectomy.
Among men who had undergone radical prostatectomy, daily consumption of a soy protein supplement did not reduce or delay development of biochemical recurrence of prostate cancer
No reduction in biochemical recurrence within two years of radical prostatectomy, despite daily soy protein ingestion.
Worse outcomes are seen for African-American men with low-risk prostate cancer who undergo prostatectomy, according to a study published online in the Journal of Clinical Oncology.
Finding in men with similar prostate conditions undergoing watchful waiting versus immediate surgery proved to be similar.
A recent study uncovered no significant differences in morbidity or recurrence rates between men with prostate cancer who underwent conformal radiotherapy (CRT) or those receiving newer intensity-modulated radiotherapy (IMRT) following prostatectomy.
No significant difference in morbidity, cancer control for men treated post-prostatectomy using Intensity-modulated radiotherapy (IMRT) over conformal radiotherapy (CRT).
Significant associations seen in men's urinary and sexual function based on surgeon performing radical prostatectomy.
Late recurrence of prostate cancer is rare if PSA is less than 0.2 ng/mL, the surgical PSA definition of cancer control, 15 years after treatment with radiation therapy.
Researchers assessed why two studies comparing prostatectomy with watchful waiting had conflicting findings in absolute mortality difference.
A posttreatment assessment of men who underwent treatment for prostate cancer revealed a side effect that has a significant impact on patients.
Administering radiotherapy after prostatectomy helped nearly two-thirds of users in a recent study remain free of prostate cancer after 10 years.
Compared with prostatectomy, surveillance will likely reduce prostate cancer-specific survival only slightly and greatly enhance quality of life.
Simulation model compares long-term effect of active surveillance versus immediate prostatectomy.
Aspirin primarily contributes to reduction for localized cancer treated with prostatectomy, radiotherapy.
Radical prostatectomy did not significantly reduce all-cause or prostate cancer mortality compared with observation in men with localized disease.
Preoperative MRI led to a change in surgical plan in 27 percent of robot-assisted prostatectomies.
The results of a large study indicate that radical prostatectomy offers durable cancer control and survival rates 20 years following surgery for men with locally advanced prostate cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|